Welcome to our dedicated page for FINDIT news (Ticker: FDIT), a resource for investors and traders seeking the latest updates and insights on FINDIT stock.
FINDIT INC (FDIT) operates at the intersection of digital content innovation and advanced healthcare solutions, making its news coverage essential for understanding cross-industry developments. This dedicated hub provides verified updates across both core business segments: the Findit.com content management platform and regenerative biotherapeutics research.
Investors and industry observers will find comprehensive coverage of earnings reports, technology partnerships, medical device approvals, and strategic acquisitions. The curated news selection enables efficient tracking of how FDIT's dual focus creates synergies between digital engagement tools and healthcare analytics advancements.
Key update categories include product launches in non-invasive medical devices, platform enhancements for content creators, intellectual property developments, and financial performance across business units. All content is sourced directly from company filings and official communications to ensure reliability.
Bookmark this page for streamlined access to FDIT's evolving story as it pioneers integrated solutions in digital visibility and predictive healthcare technologies. Regular updates provide the necessary context to assess the company's unique position in converging tech and biotech markets.
BioRegenx, Inc. has announced a new peer-reviewed study published in Pediatric Critical Care Medicine, focusing on glycocalyx biomarkers in children with sepsis. The study, conducted by Jaime Fernández-Sarmiento and colleagues, utilized the GlycoCheck™ system to assess the impact of unbalanced and balanced crystalloids on the endothelial glycocalyx. Findings revealed that unbalanced fluids lead to glycocalyx degradation, heightening risks of vascular permeability and kidney failure. The GlycoCheck system, FDA registered, has been featured in over 100 studies and is crucial for monitoring microvascular health. Ongoing studies are further evaluating their Endocalyx Pro™ supplement.
BioRegenx, Inc. and Findit, Inc. have announced a merger agreement as BioRegenx reveals a new peer-reviewed study on
Endocalyx Pro™ in the International Journal of Molecular Sciences. The research indicates that Endocalyx Pro
restores and protects the endothelial glycocalyx in kidney patients exposed to toxic hemodialysis plasma. Damage to
this glycocalyx is linked to increased cardiovascular risks among Chronic Kidney Disease patients. The study indicates
Endocalyx Pro can prevent glycocalyx damage and shows effective results in mouse models. The product is patented and
distributed by Microvascular Health Solutions.
Findit, Inc. (OTC PINK:FDIT) has announced a merger with BioRegenx, Inc., approved by both boards, expected to close in Q1 2023, pending regulatory approval. This deal results in BioRegenx controlling 90% of Findit’s voting securities, with significant stock exchanges occurring. A reverse stock split of 1 for 25 is planned to attract institutional investors. BioRegenx, focusing on regenerative healthcare, aims to enhance Findit's marketing and product offerings, leveraging its subsidiaries and patented technologies.
Findit, Inc. (OTC PINK:FDIT) has updated its Investor Relations page to assist investors in transferring paper certificates to Book-Entry shares, following their recent switch to Clear Trust as their Transfer Agent. Secretary Tom Powers invites inquiries directly and emphasizes ongoing efforts in company growth, including technology enhancements and new client acquisition, alongside the preparation of quarterly reports and a forthcoming Shareholder update. Findit.com, the company's social media platform, enables enhanced brand visibility through content management and indexing in major search engines.
Findit, Inc. (OTC PINK:FDIT) announced a new partnership with Rentalz.com, a vacation rental marketplace under Resortia Group. Rentalz differentiates itself by collaborating solely with professional property managers and not charging guest booking fees, allowing guests to save an average of 10% compared to major competitors like Airbnb and VRBO. The platform boasts around 50,000 listings nationwide and aims for rapid expansion. Findit will aid in enhancing Rentalz's web presence through SEO and content services, targeting improved traffic without incurring high Pay-Per-Click costs.
FAQ
What is the current stock price of FINDIT (FDIT)?
What is the market cap of FINDIT (FDIT)?
